Resolvin D1-d5

Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α-mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].

Product Specifications

CAS Number

[1881277-32-2]

Product Name Alternative

RvD1-d5

UNSPSC

12352211

Hazard Statement

H225, H350

Target

Endogenous Metabolite; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Inflammation/Immunology

Concentration

262.11 µM * 100 μL in Ethanol

Purity

99.2

Solubility

10 mM in DMSO

Smiles

O[C@H](/C=C/C=C\C=C\C=C\[C@H]([C@H](C/C=C\CCC(O)=O)O)O)C/C=C\C([2H])(C([2H])([2H])[2H])[2H]

Molecular Formula

C22H27D5O5

Molecular Weight

381.52

Precautions

H225, H350

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Schmid M, et al. Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32. J Immunol. 2016 Apr 15;196 (8) :3429-37.|[3]Gao Y, et al. Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome. J Immunol. 2017 Aug 9. pii: ji1700315.|[4]Benabdoun HA, et al. In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. Arthritis Res Ther. 2019 Mar 12;21 (1) :72.